{"success":true,"data":{"pressRelease":{"id":"109385","rtpr_id":"nGNX2hmyTB","ticker":"ASPI","exchange":"NASDAQ","all_tickers":["ASPI"],"title":"ASP Isotopes to Participate in Citi’s 2026 Natural Resources Conference","author":"Globe Newswire","published_at":"2026-08-05T12:00:01.424Z","article_body":"DALLAS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI)\n(“ASP Isotopes” or the “Company”), an advanced materials company\nfocused on developing technologies and processes for the production of\ncritical materials used in multiple industries, today announced that it will\nhost investor meetings at Citi's 2026 Natural Resources Conference on\nThursday, August 13, 2026, in Las Vegas, Nevada.\n\nThe latest investor presentation can be accessed under the Investors tab on\nthe ASP Isotopes website.\n\nAbout ASP Isotopes Inc.\n\nASP Isotopes is developing a differentiated isotope enrichment platform to\nstrengthen global supply chain access to critical materials used in nuclear\nmedicine, next-generation semiconductors, and nuclear energy. The Company’s\nproprietary technologies, the Aerodynamic Separation Process (“ASP\ntechnology”) and Quantum Enrichment (“QE technology”), are designed to\nenable the production of isotopes for a range of industrial and advanced\ntechnology applications. ASP Isotopes operates isotope enrichment facilities\nin Pretoria, South Africa, focused on the enrichment of low atomic mass\nelements, or light isotopes. For more information, please visit\nwww.aspisotopes.com.\n\nImportant Additional Information and Where to Find It\n\nIn connection with the proposed merger and related transactions (the\n“Proposed Transactions”) involving ENDRA Life Sciences Inc. (“ENDRA”),\nASP Isotopes, Renergen, a subsidiary of ASP Isotopes (“Renergen”), and\nNoble Africa, a subsidiary of ASP Isotopes and holding company for Renergen\n(“Noble Africa”), ENDRA intends to file relevant materials with the U.S.\nSecurities and Exchange Commission (the “SEC”), including a registration\nstatement on Form S-4 (the “Form S-4”) that will contain a proxy statement\n(the “Proxy Statement”) and prospectus. This communication is not a\nsubstitute for the Form S-4, the Proxy Statement or for any other document\nthat ENDRA may file with the SEC and/or send to its stockholders in connection\nwith the Proposed Transactions. INVESTORS AND STOCKHOLDERS OF ENDRA ARE URGED\nTO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS\nTHAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO\nTHESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME\nAVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ENDRA, ASP\nISOTOPES, RENERGEN, NOBLE AFRICA, THE PROPOSED TRANSACTIONS AND RELATED\nMATTERS. Investors and stockholders will be able to obtain free copies of the\nForm S-4, the Proxy Statement and other documents filed by ENDRA and ASP\nIsotopes with the SEC (when they become available) through the website\nmaintained by the SEC at www.sec.gov. ENDRA’s Internet website address is\nwww.endrainc.com. ENDRA’s Annual Report on Form 10-K, Quarterly Reports on\nForm 10-Q, Current Reports on Form 8-K, including exhibits, and amendments to\nthose reports filed or furnished pursuant to Section 13(a) or 15(d) of the\nExchange Act are available free of charge through the investor relations page\nof its Internet website as soon as reasonably practicable after it\nelectronically files such material with, or furnishes such material to, the\nSEC.\n\nParticipants in the Solicitation\n\nENDRA, ASP Isotopes, Renergen, Noble Africa, and their respective directors\nand managers and certain of their executive officers and other members of\nmanagement may be deemed to be participants in the solicitation of proxies\nfrom ENDRA’s stockholders in connection with the Proposed Transactions under\nthe rules of the SEC. Information about ENDRA’s directors and executive\nofficers, including a description of their interests in ENDRA, is included in\nENDRA’s most recent Annual Report on Form 10-K for the year ended December\n31, 2025. Information about ASP Isotopes’ directors and executive officers,\nincluding a description of their interests in ASP Isotopes, is included in ASP\nIsotopes’ most recent Annual Report on Form 10-K for the year ended December\n31, 2025. Additional information regarding the persons who may be deemed\nparticipants in the proxy solicitations, including the directors and executive\nofficers of Renergen, and a description of their direct and indirect\ninterests, by security holdings or otherwise, will also be included in the\nForm S-4, the Proxy Statement and other relevant materials to be filed with\nthe SEC when they become available. These documents can be obtained free of\ncharge from the sources indicated above.\n\nNo Offer or Solicitation\n\nThis press release is not intended to and does not constitute a solicitation\nof a proxy, consent or approval with respect to any securities or in respect\nof the Proposed Transactions or an offer to sell or the solicitation of an\noffer to subscribe for or buy or an invitation to purchase or subscribe for\nany securities pursuant to the Proposed Transactions or otherwise, nor shall\nthere be any sale, issuance or transfer of securities in any jurisdiction in\ncontravention of applicable law. No offering of securities shall be made\nexcept by means of a prospectus meeting the requirements of Section 10 of the\nSecurities Act of 1933, as amended, and otherwise in accordance with\napplicable law, or an exemption therefrom. Subject to certain exceptions to be\napproved by the relevant regulators or certain facts to be ascertained, the\npublic offer will not be made directly or indirectly, in or into any\njurisdiction where to do so would constitute a violation of the laws of such\njurisdiction, or by use of the mails or by any means or instrumentality\n(including without limitation, facsimile transmission, telephone and the\ninternet) of interstate or foreign commerce, or any facility of a national\nsecurities exchange, of any such jurisdiction.\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the safe harbor provisions of the Private Securities Litigation\nReform Act of 1995. Forward-looking statements are neither historical facts\nnor assurances of future performance. Instead, they are based only on the\nCompany’s current beliefs, expectations, and assumptions regarding the\nfuture of the Company’s business, future plans and strategies, projections,\nanticipated events and trends, the economy, and other future conditions.\nForward-looking statements can be identified by words such as\n“anticipates,” “believes,” “could,” “estimates,”\n“expects,” “intends,” “may,” “might,” “plans,”\n“projects,” “will,” and words of a similar nature. Examples of\nforward-looking statements include, but are not limited to, statements\nregarding the Company’s business strategy and market opportunity, and\nexpectations regarding the structure, timing and completion of the Proposed\nTransactions. Because forward-looking statements relate to the future, they\nare subject to inherent uncertainties, risks, and changes in circumstances\nthat are difficult to predict, many of which are outside of the Company’s\ncontrol. Actual results, financial condition, and events may differ materially\nfrom those indicated in the forward-looking statements based upon a number of\nfactors. Forward-looking statements are not a guarantee of future performance\nor developments. You are strongly cautioned that reliance on any\nforward-looking statements involves known and unknown risks and uncertainties.\nTherefore, you should not rely on any of these forward-looking statements.\n\nThere are many important factors that could cause actual results and financial\ncondition to differ materially from those indicated in the forward-looking\nstatements, including, but not limited to: the outcomes of various strategies\nand projects undertaken by the Company; the potential impact of laws or\ngovernment regulations or policies in South Africa, the United Kingdom or\nelsewhere; the Company’s future capital requirements and sources and uses of\ncash; the Company’s ability to obtain funding for its operations and future\ngrowth; the Company’s reliance on the efforts of third parties; the\nCompany’s ability to complete the construction and commissioning of its\nenrichment plants or to commercialize isotopes using the ASP technology or the\nQuantum Enrichment Process; the Company’s ability to obtain regulatory\napprovals for the production and distribution of isotopes; the financial terms\nof any current and future commercial arrangements; the Company’s ability to\ncomplete certain transactions and realize anticipated benefits from\nacquisitions and contracts; dependence on the Company’s Intellectual\nProperty (IP) rights, certain IP rights of third parties; the competitive\nnature of the Company’s industry; the risk that the conditions to the\nclosing or consummation of the Proposed Transactions are not satisfied,\nincluding the failure to timely obtain approval of the Proposed Transactions\nfrom ENDRA stockholders, if at all; uncertainties as to the timing of the\nconsummation of the Proposed Transactions and the ability of each of ENDRA and\nNoble Africa to consummate the Proposed Transactions; and the other risks and\nuncertainties disclosed in Part I, Item 1A. “Risk Factors” of the\nCompany’s Annual Report on Form 10-K for the fiscal year ended December 31,\n2025 (as amended) and in the Company’s subsequent reports filed with the\nSEC.\n\nAny forward-looking statement made by the Company in this press release is\nbased only on information currently available to the Company and speaks only\nas of the date on which it is made. The Company undertakes no obligation to\npublicly update any forward-looking statement, whether as a result of new\ninformation, future developments or otherwise. No information in this press\nrelease should be interpreted as an indication of future success, revenues,\nresults of operations, or stock price. All forward-looking statements herein\nare qualified by reference to the cautionary statements set forth herein and\nshould not be relied upon.\n\nContact\n\nIR@ASPIsotopes.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ae36ec1e-ca52-4326-b922-6ccaab89d475)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2hmyTB","title":"ASP Isotopes to Participate in Citi’s 2026 Natural Resources Conference","author":"Globe Newswire","ticker":"ASPI","created":"2026-08-05T12:00:01.424Z","tickers":["ASPI"],"exchange":"NASDAQ","article_body":"DALLAS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI)\n(“ASP Isotopes” or the “Company”), an advanced materials company\nfocused on developing technologies and processes for the production of\ncritical materials used in multiple industries, today announced that it will\nhost investor meetings at Citi's 2026 Natural Resources Conference on\nThursday, August 13, 2026, in Las Vegas, Nevada.\n\nThe latest investor presentation can be accessed under the Investors tab on\nthe ASP Isotopes website.\n\nAbout ASP Isotopes Inc.\n\nASP Isotopes is developing a differentiated isotope enrichment platform to\nstrengthen global supply chain access to critical materials used in nuclear\nmedicine, next-generation semiconductors, and nuclear energy. The Company’s\nproprietary technologies, the Aerodynamic Separation Process (“ASP\ntechnology”) and Quantum Enrichment (“QE technology”), are designed to\nenable the production of isotopes for a range of industrial and advanced\ntechnology applications. ASP Isotopes operates isotope enrichment facilities\nin Pretoria, South Africa, focused on the enrichment of low atomic mass\nelements, or light isotopes. For more information, please visit\nwww.aspisotopes.com.\n\nImportant Additional Information and Where to Find It\n\nIn connection with the proposed merger and related transactions (the\n“Proposed Transactions”) involving ENDRA Life Sciences Inc. (“ENDRA”),\nASP Isotopes, Renergen, a subsidiary of ASP Isotopes (“Renergen”), and\nNoble Africa, a subsidiary of ASP Isotopes and holding company for Renergen\n(“Noble Africa”), ENDRA intends to file relevant materials with the U.S.\nSecurities and Exchange Commission (the “SEC”), including a registration\nstatement on Form S-4 (the “Form S-4”) that will contain a proxy statement\n(the “Proxy Statement”) and prospectus. This communication is not a\nsubstitute for the Form S-4, the Proxy Statement or for any other document\nthat ENDRA may file with the SEC and/or send to its stockholders in connection\nwith the Proposed Transactions. INVESTORS AND STOCKHOLDERS OF ENDRA ARE URGED\nTO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS\nTHAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO\nTHESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME\nAVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ENDRA, ASP\nISOTOPES, RENERGEN, NOBLE AFRICA, THE PROPOSED TRANSACTIONS AND RELATED\nMATTERS. Investors and stockholders will be able to obtain free copies of the\nForm S-4, the Proxy Statement and other documents filed by ENDRA and ASP\nIsotopes with the SEC (when they become available) through the website\nmaintained by the SEC at www.sec.gov. ENDRA’s Internet website address is\nwww.endrainc.com. ENDRA’s Annual Report on Form 10-K, Quarterly Reports on\nForm 10-Q, Current Reports on Form 8-K, including exhibits, and amendments to\nthose reports filed or furnished pursuant to Section 13(a) or 15(d) of the\nExchange Act are available free of charge through the investor relations page\nof its Internet website as soon as reasonably practicable after it\nelectronically files such material with, or furnishes such material to, the\nSEC.\n\nParticipants in the Solicitation\n\nENDRA, ASP Isotopes, Renergen, Noble Africa, and their respective directors\nand managers and certain of their executive officers and other members of\nmanagement may be deemed to be participants in the solicitation of proxies\nfrom ENDRA’s stockholders in connection with the Proposed Transactions under\nthe rules of the SEC. Information about ENDRA’s directors and executive\nofficers, including a description of their interests in ENDRA, is included in\nENDRA’s most recent Annual Report on Form 10-K for the year ended December\n31, 2025. Information about ASP Isotopes’ directors and executive officers,\nincluding a description of their interests in ASP Isotopes, is included in ASP\nIsotopes’ most recent Annual Report on Form 10-K for the year ended December\n31, 2025. Additional information regarding the persons who may be deemed\nparticipants in the proxy solicitations, including the directors and executive\nofficers of Renergen, and a description of their direct and indirect\ninterests, by security holdings or otherwise, will also be included in the\nForm S-4, the Proxy Statement and other relevant materials to be filed with\nthe SEC when they become available. These documents can be obtained free of\ncharge from the sources indicated above.\n\nNo Offer or Solicitation\n\nThis press release is not intended to and does not constitute a solicitation\nof a proxy, consent or approval with respect to any securities or in respect\nof the Proposed Transactions or an offer to sell or the solicitation of an\noffer to subscribe for or buy or an invitation to purchase or subscribe for\nany securities pursuant to the Proposed Transactions or otherwise, nor shall\nthere be any sale, issuance or transfer of securities in any jurisdiction in\ncontravention of applicable law. No offering of securities shall be made\nexcept by means of a prospectus meeting the requirements of Section 10 of the\nSecurities Act of 1933, as amended, and otherwise in accordance with\napplicable law, or an exemption therefrom. Subject to certain exceptions to be\napproved by the relevant regulators or certain facts to be ascertained, the\npublic offer will not be made directly or indirectly, in or into any\njurisdiction where to do so would constitute a violation of the laws of such\njurisdiction, or by use of the mails or by any means or instrumentality\n(including without limitation, facsimile transmission, telephone and the\ninternet) of interstate or foreign commerce, or any facility of a national\nsecurities exchange, of any such jurisdiction.\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the safe harbor provisions of the Private Securities Litigation\nReform Act of 1995. Forward-looking statements are neither historical facts\nnor assurances of future performance. Instead, they are based only on the\nCompany’s current beliefs, expectations, and assumptions regarding the\nfuture of the Company’s business, future plans and strategies, projections,\nanticipated events and trends, the economy, and other future conditions.\nForward-looking statements can be identified by words such as\n“anticipates,” “believes,” “could,” “estimates,”\n“expects,” “intends,” “may,” “might,” “plans,”\n“projects,” “will,” and words of a similar nature. Examples of\nforward-looking statements include, but are not limited to, statements\nregarding the Company’s business strategy and market opportunity, and\nexpectations regarding the structure, timing and completion of the Proposed\nTransactions. Because forward-looking statements relate to the future, they\nare subject to inherent uncertainties, risks, and changes in circumstances\nthat are difficult to predict, many of which are outside of the Company’s\ncontrol. Actual results, financial condition, and events may differ materially\nfrom those indicated in the forward-looking statements based upon a number of\nfactors. Forward-looking statements are not a guarantee of future performance\nor developments. You are strongly cautioned that reliance on any\nforward-looking statements involves known and unknown risks and uncertainties.\nTherefore, you should not rely on any of these forward-looking statements.\n\nThere are many important factors that could cause actual results and financial\ncondition to differ materially from those indicated in the forward-looking\nstatements, including, but not limited to: the outcomes of various strategies\nand projects undertaken by the Company; the potential impact of laws or\ngovernment regulations or policies in South Africa, the United Kingdom or\nelsewhere; the Company’s future capital requirements and sources and uses of\ncash; the Company’s ability to obtain funding for its operations and future\ngrowth; the Company’s reliance on the efforts of third parties; the\nCompany’s ability to complete the construction and commissioning of its\nenrichment plants or to commercialize isotopes using the ASP technology or the\nQuantum Enrichment Process; the Company’s ability to obtain regulatory\napprovals for the production and distribution of isotopes; the financial terms\nof any current and future commercial arrangements; the Company’s ability to\ncomplete certain transactions and realize anticipated benefits from\nacquisitions and contracts; dependence on the Company’s Intellectual\nProperty (IP) rights, certain IP rights of third parties; the competitive\nnature of the Company’s industry; the risk that the conditions to the\nclosing or consummation of the Proposed Transactions are not satisfied,\nincluding the failure to timely obtain approval of the Proposed Transactions\nfrom ENDRA stockholders, if at all; uncertainties as to the timing of the\nconsummation of the Proposed Transactions and the ability of each of ENDRA and\nNoble Africa to consummate the Proposed Transactions; and the other risks and\nuncertainties disclosed in Part I, Item 1A. “Risk Factors” of the\nCompany’s Annual Report on Form 10-K for the fiscal year ended December 31,\n2025 (as amended) and in the Company’s subsequent reports filed with the\nSEC.\n\nAny forward-looking statement made by the Company in this press release is\nbased only on information currently available to the Company and speaks only\nas of the date on which it is made. The Company undertakes no obligation to\npublicly update any forward-looking statement, whether as a result of new\ninformation, future developments or otherwise. No information in this press\nrelease should be interpreted as an indication of future success, revenues,\nresults of operations, or stock price. All forward-looking statements herein\nare qualified by reference to the cautionary statements set forth herein and\nshould not be relied upon.\n\nContact\n\nIR@ASPIsotopes.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ae36ec1e-ca52-4326-b922-6ccaab89d475)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-05T12:00:01.656685069Z","server_sent_at_ms":1785931201656},"received_at":"2026-08-05T12:00:01.708Z","source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339254/0/en/asp-isotopes-to-participate-in-citi-s-2026-natural-resources-conference.html"},"analysis":{"id":"98391","press_release_id":"109385","analysis_json":{"industry":{"label":"Chemicals","sector":"Materials"},"redFlags":[],"eventType":"other","narrative":"ASP Isotopes announced that management will host investor meetings at Citi's 2026 Natural Resources Conference in Las Vegas on August 13, 2026.\n\nThe company noted that its latest investor presentation is accessible on the Investors section of its website.\n\nThe release also referenced the pending proposed transactions involving ENDRA Life Sciences Inc., Renergen, and Noble Africa, including standard boilerplate regarding upcoming SEC filings.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor conference attendance."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[],"products":["Aerodynamic Separation Process","Quantum Enrichment"],"companies":[{"name":"ASP Isotopes Inc.","ticker":"ASPI"},{"name":"Citi","relationship":"conference organizer"},{"name":"ENDRA Life Sciences Inc.","ticker":"ENDRA","relationship":"target"},{"name":"Renergen","relationship":"subsidiary"},{"name":"Noble Africa","relationship":"subsidiary"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of conference participation with no new financial data, operational milestones, or material business developments disclosed."},"tickerRelevance":{"others":[{"ticker":"ENDRA","relevance":"target"}],"primary":"ASPI"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small_cap","eventGravity":"conference_attendance"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"ASP Isotopes announced that management will host investor meetings at Citi's 2026 Natural Resources Conference in Las Vegas on August 13, 2026.\n\nThe company noted that its latest investor presentation is accessible on the Investors section of its website.\n\nThe release also referenced the pending proposed transactions involving ENDRA Life Sciences Inc., Renergen, and Noble Africa, including standard boilerplate regarding upcoming SEC filings.","key_figures":null,"named_entities":{"people":[],"products":["Aerodynamic Separation Process","Quantum Enrichment"],"companies":[{"name":"ASP Isotopes Inc.","ticker":"ASPI"},{"name":"Citi","relationship":"conference organizer"},{"name":"ENDRA Life Sciences Inc.","ticker":"ENDRA","relationship":"target"},{"name":"Renergen","relationship":"subsidiary"},{"name":"Noble Africa","relationship":"subsidiary"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-05T16:22:00.700Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"small_cap","eventGravity":"conference_attendance"}},"durationMs":443548,"modelName":"glm-4.7"}}